Compare IMC & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMC | OBX |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.3M | 861.1M |
| IPO Year | 2026 | 2026 |
| Metric | IMC | OBX |
|---|---|---|
| Price | $10.72 | $14.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 106.8K | ★ 300.4K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $11.52 |
| 52 Week High | $12.00 | $39.00 |
| Indicator | IMC | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 47.42 |
| Support Level | $6.23 | $11.84 |
| Resistance Level | $11.84 | $19.97 |
| Average True Range (ATR) | 1.16 | 1.09 |
| MACD | 0.48 | 0.40 |
| Stochastic Oscillator | 73.33 | 56.78 |
IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.